CACNA1G and melanoma: TTCCs, the Cav3.1 and Cav3.2 isoforms in particular, have been found to be overexpressed in prostate [26,27], breast [28,29,30], ovarian [31,32], colon [33] and esophageal [34] cancers, retinoblastoma [29], glioblastoma [35], hepatocellular carcinoma [36], and melanoma [18].